Jaimin R. Shah

Sr. Vice President, R&D and Operations

Therapeutic Areas

Drug	Indication	Phase
Complex Generic / 505(b)(2) Pipeline	Various (Oncology, Immunology, and other areas)	Pre-clinical to Phase 3 (Bioequivalence)